TLDR
- AbbVie (ABBV) shares fell 0.60% to $284.25 despite the $2.54B Disco cancer deal.
- Disco will receive $40M upfront and could earn $2.5B in milestone payments.
- The partnership targets solid tumors using next-generation bispecific antibodies.
- Disco will lead drug discovery, while AbbVie can license selected programs.
- Disco expects to select a cancer drug candidate in the second half of 2027.
AbbVie Inc. (ABBV) stock declined 0.60% to $284.25, losing $1.71 despite announcing a major cancer research agreement. The pharmaceutical company partnered with Germany-based Disco Pharmaceuticals in a deal worth up to $2.54 billion. The collaboration expands AbbVie’s cancer pipeline through new antibody treatments targeting difficult-to-treat solid tumors.
AbbVie Stock Slips Despite $2.54 Billion Cancer Partnership
AbbVie shares faced early selling pressure after closing the previous session at $285.96. Meanwhile, the company secured access to Disco’s research platform through a new option-to-license agreement. The partnership strengthens AbbVie’s efforts to develop targeted cancer medicines.
Under the agreement, Disco will receive $40 million upfront and potentially $2.5 billion in additional milestone payments. The payments depend on licensing decisions, development progress, and other agreed conditions. Disco could also earn tiered royalties from worldwide sales of resulting treatments.
The companies will focus on AND-gated bispecific antibodies for solid tumors with significant medical needs. These treatments recognize cancer cells through two specific proteins appearing together. This approach aims to improve tumor targeting while reducing damage to healthy tissue.
Disco Pharmaceuticals to Lead Early Cancer Drug Research
Disco will manage initial research and discovery using its proprietary DiscoTech platform. The technology maps proteins on cancer cell surfaces to identify suitable treatment targets. AbbVie will contribute its expertise in cancer biology and target selection.
Following the research phase, AbbVie can exercise exclusive licensing options for selected development programs. However, neither company disclosed the number of programs covered by the agreement. Both companies also withheld specific timelines for clinical development.
Disco currently researches potential treatments for small-cell lung cancer and colorectal cancer. The company expects to select a development candidate during the second half of 2027. Meanwhile, its collaboration with AbbVie supports further research into precision cancer treatments.
AbbVie Expands Cancer Pipeline Amid Growing Industry Competition
AbbVie has continued expanding its presence in bispecific antibody treatments through major pharmaceutical partnerships. In January, the company paid RemeGen $650 million upfront for rights outside China. That agreement covered a bispecific cancer treatment targeting solid tumors.
Other pharmaceutical companies have also committed substantial funding to similar cancer research programs. Bristol Myers Squibb partnered with BioNTech in an agreement worth up to $11.1 billion. Meanwhile, UCB acquired Candid Therapeutics for $2.2 billion, reflecting continued industry interest.
AbbVie’s latest agreement adds another early-stage program to its expanding oncology portfolio. The milestone-based structure spreads potential payments across future research and development achievements. However, the collaboration must advance through drug discovery and clinical testing before generating commercial revenue.





